The patient perspective

Quality of life in advanced heart failure with frequent hospitalisations

Markku S. Nieminen, Kenneth Dickstein, Cândida Fonseca, Jose Magaña Serrano, John Parissis, Francesco Fedele, Gerhard Wikström, Piergiuseppe Agostoni, Shaul Atar, Loant Baholli, Dulce Brito, Josep Comín Colet, I. Édes, Juan E. Gómez Mesa, Vojka Gorjup, Eduardo Herrera Garza, José R. González Juanatey, Nenad Karanovic, Apostolos Karavidas, Igor Katsytadze & 14 others Matti Kivikko, Simon Matskeplishvili, B. Merkely, Fabrizio Morandi, Angel Novoa, Fabrizio Oliva, Petr Ostadal, Antonio Pereira-Barretto, Piero Pollesello, Alain Rudiger, Robert H G Schwinger, Manfred Wieser, Igor Yavelov, Robert Zymliński

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.

Original languageEnglish
Pages (from-to)256-264
Number of pages9
JournalInternational Journal of Cardiology
Volume191
DOIs
Publication statusPublished - Jul 15 2015

Fingerprint

Hospitalization
Heart Failure
Quality of Life
Critical Care
Cardiology
Vasodilator Agents
Health Personnel
Uncertainty
Consensus
Hemodynamics
Clinical Trials
Exercise
Psychology
Survival
Therapeutics
Research

Keywords

  • Advanced heart failure
  • Levosimendan
  • Nesiritide
  • Nitroprusside
  • Quality of life
  • Trade-off

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Nieminen, M. S., Dickstein, K., Fonseca, C., Serrano, J. M., Parissis, J., Fedele, F., ... Zymliński, R. (2015). The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology, 191, 256-264. https://doi.org/10.1016/j.ijcard.2015.04.235

The patient perspective : Quality of life in advanced heart failure with frequent hospitalisations. / Nieminen, Markku S.; Dickstein, Kenneth; Fonseca, Cândida; Serrano, Jose Magaña; Parissis, John; Fedele, Francesco; Wikström, Gerhard; Agostoni, Piergiuseppe; Atar, Shaul; Baholli, Loant; Brito, Dulce; Colet, Josep Comín; Édes, I.; Gómez Mesa, Juan E.; Gorjup, Vojka; Garza, Eduardo Herrera; González Juanatey, José R.; Karanovic, Nenad; Karavidas, Apostolos; Katsytadze, Igor; Kivikko, Matti; Matskeplishvili, Simon; Merkely, B.; Morandi, Fabrizio; Novoa, Angel; Oliva, Fabrizio; Ostadal, Petr; Pereira-Barretto, Antonio; Pollesello, Piero; Rudiger, Alain; Schwinger, Robert H G; Wieser, Manfred; Yavelov, Igor; Zymliński, Robert.

In: International Journal of Cardiology, Vol. 191, 15.07.2015, p. 256-264.

Research output: Contribution to journalArticle

Nieminen, MS, Dickstein, K, Fonseca, C, Serrano, JM, Parissis, J, Fedele, F, Wikström, G, Agostoni, P, Atar, S, Baholli, L, Brito, D, Colet, JC, Édes, I, Gómez Mesa, JE, Gorjup, V, Garza, EH, González Juanatey, JR, Karanovic, N, Karavidas, A, Katsytadze, I, Kivikko, M, Matskeplishvili, S, Merkely, B, Morandi, F, Novoa, A, Oliva, F, Ostadal, P, Pereira-Barretto, A, Pollesello, P, Rudiger, A, Schwinger, RHG, Wieser, M, Yavelov, I & Zymliński, R 2015, 'The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations', International Journal of Cardiology, vol. 191, pp. 256-264. https://doi.org/10.1016/j.ijcard.2015.04.235
Nieminen, Markku S. ; Dickstein, Kenneth ; Fonseca, Cândida ; Serrano, Jose Magaña ; Parissis, John ; Fedele, Francesco ; Wikström, Gerhard ; Agostoni, Piergiuseppe ; Atar, Shaul ; Baholli, Loant ; Brito, Dulce ; Colet, Josep Comín ; Édes, I. ; Gómez Mesa, Juan E. ; Gorjup, Vojka ; Garza, Eduardo Herrera ; González Juanatey, José R. ; Karanovic, Nenad ; Karavidas, Apostolos ; Katsytadze, Igor ; Kivikko, Matti ; Matskeplishvili, Simon ; Merkely, B. ; Morandi, Fabrizio ; Novoa, Angel ; Oliva, Fabrizio ; Ostadal, Petr ; Pereira-Barretto, Antonio ; Pollesello, Piero ; Rudiger, Alain ; Schwinger, Robert H G ; Wieser, Manfred ; Yavelov, Igor ; Zymliński, Robert. / The patient perspective : Quality of life in advanced heart failure with frequent hospitalisations. In: International Journal of Cardiology. 2015 ; Vol. 191. pp. 256-264.
@article{2d10207d363f45ff9e347d77de967eb5,
title = "The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations",
abstract = "End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.",
keywords = "Advanced heart failure, Levosimendan, Nesiritide, Nitroprusside, Quality of life, Trade-off",
author = "Nieminen, {Markku S.} and Kenneth Dickstein and C{\^a}ndida Fonseca and Serrano, {Jose Maga{\~n}a} and John Parissis and Francesco Fedele and Gerhard Wikstr{\"o}m and Piergiuseppe Agostoni and Shaul Atar and Loant Baholli and Dulce Brito and Colet, {Josep Com{\'i}n} and I. {\'E}des and {G{\'o}mez Mesa}, {Juan E.} and Vojka Gorjup and Garza, {Eduardo Herrera} and {Gonz{\'a}lez Juanatey}, {Jos{\'e} R.} and Nenad Karanovic and Apostolos Karavidas and Igor Katsytadze and Matti Kivikko and Simon Matskeplishvili and B. Merkely and Fabrizio Morandi and Angel Novoa and Fabrizio Oliva and Petr Ostadal and Antonio Pereira-Barretto and Piero Pollesello and Alain Rudiger and Schwinger, {Robert H G} and Manfred Wieser and Igor Yavelov and Robert Zymliński",
year = "2015",
month = "7",
day = "15",
doi = "10.1016/j.ijcard.2015.04.235",
language = "English",
volume = "191",
pages = "256--264",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The patient perspective

T2 - Quality of life in advanced heart failure with frequent hospitalisations

AU - Nieminen, Markku S.

AU - Dickstein, Kenneth

AU - Fonseca, Cândida

AU - Serrano, Jose Magaña

AU - Parissis, John

AU - Fedele, Francesco

AU - Wikström, Gerhard

AU - Agostoni, Piergiuseppe

AU - Atar, Shaul

AU - Baholli, Loant

AU - Brito, Dulce

AU - Colet, Josep Comín

AU - Édes, I.

AU - Gómez Mesa, Juan E.

AU - Gorjup, Vojka

AU - Garza, Eduardo Herrera

AU - González Juanatey, José R.

AU - Karanovic, Nenad

AU - Karavidas, Apostolos

AU - Katsytadze, Igor

AU - Kivikko, Matti

AU - Matskeplishvili, Simon

AU - Merkely, B.

AU - Morandi, Fabrizio

AU - Novoa, Angel

AU - Oliva, Fabrizio

AU - Ostadal, Petr

AU - Pereira-Barretto, Antonio

AU - Pollesello, Piero

AU - Rudiger, Alain

AU - Schwinger, Robert H G

AU - Wieser, Manfred

AU - Yavelov, Igor

AU - Zymliński, Robert

PY - 2015/7/15

Y1 - 2015/7/15

N2 - End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.

AB - End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.

KW - Advanced heart failure

KW - Levosimendan

KW - Nesiritide

KW - Nitroprusside

KW - Quality of life

KW - Trade-off

UR - http://www.scopus.com/inward/record.url?scp=84941621522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941621522&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.04.235

DO - 10.1016/j.ijcard.2015.04.235

M3 - Article

VL - 191

SP - 256

EP - 264

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -